Kiniksa Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Kiniksa Pharmaceuticals's estimated annual revenue is currently $19.8M per year.(i)
  • Kiniksa Pharmaceuticals's estimated revenue per employee is $88,000
  • Kiniksa Pharmaceuticals's total funding is $400M.
  • Kiniksa Pharmaceuticals's current valuation is $780.5M. (January 2022)

Employee Data

  • Kiniksa Pharmaceuticals has 225 Employees.(i)
  • Kiniksa Pharmaceuticals grew their employee count by 13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Kiniksa is a publicly traded biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have a pipeline of product candidates across various stages of development focused on autoinflammatory and autoimmune conditions that have the potential to address multiple indications. We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines. We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company. Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Kiniksa Pharmaceuticals News

2022-04-13 - $31.93 Million in Sales Expected for Kiniksa Pharmaceuticals ...

Bank of America dropped their price target on Kiniksa Pharmaceuticals from $37.00 to $34.00 and set a “buy” rating on the stock in a research...

2022-04-06 - Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd ...

Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Will Announce Earnings of -$0.40 Per Share. Posted by admin on Apr 12th,...

2022-04-06 - China SXT Pharmaceuticals (NASDAQ:SXTC) and Kiniksa ...

Comparatively, Kiniksa Pharmaceuticals has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Insider and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding